Ethic Inc. Purchases 43,295 Shares of Takeda Pharmaceutical Co. $TAK

Ethic Inc. raised its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 16.2% in the 3rd quarter, Holdings Channel reports. The firm owned 310,751 shares of the company’s stock after acquiring an additional 43,295 shares during the period. Ethic Inc.’s holdings in Takeda Pharmaceutical were worth $4,549,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of TAK. CWM LLC increased its stake in shares of Takeda Pharmaceutical by 37.4% in the 3rd quarter. CWM LLC now owns 9,373 shares of the company’s stock valued at $137,000 after purchasing an additional 2,551 shares during the last quarter. BSW Wealth Partners bought a new position in Takeda Pharmaceutical in the third quarter valued at about $285,000. Optas LLC acquired a new position in Takeda Pharmaceutical during the third quarter worth about $165,000. Farther Finance Advisors LLC raised its stake in Takeda Pharmaceutical by 24.5% during the third quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock worth $102,000 after acquiring an additional 1,378 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC lifted its holdings in shares of Takeda Pharmaceutical by 1.0% in the third quarter. Legacy Wealth Asset Management LLC now owns 166,482 shares of the company’s stock worth $2,437,000 after acquiring an additional 1,697 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $15.62 on Wednesday. The firm has a market capitalization of $49.70 billion, a price-to-earnings ratio of 195.23 and a beta of 0.03. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61. The business’s 50-day moving average price is $14.34 and its 200-day moving average price is $14.62. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.78.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.44. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.The company had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.